SAN FRANCISCO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...
Structure's aleniglipron elicited over 11% weight loss in a Phase II trial, sending the biotech's stock up nearly 103% as ...
Structure Therapeutics (GPCR) is stepping into the spotlight as it prepares to release topline data from its ACCESS trial of aleniglipron, an oral GLP 1 candidate for obesity, along with a same day ...
The Maine Attorney General's office has spent $10 million of its share of opioid settlement funding, with more than half ...
Discover why Structure Therapeutics Inc. is rated Strong Buy after positive Aleniglipron phase 2b obesity data. Click for ...
Shenzhen, Zhenjiang, Xiamen and Nanchang – approached developing low-carbon policies over the course of almost a decade ...
Global innovation rankings identified five urban hubs where technology had become part of everyday life rather than a distant ...
Real-time security clearances are becoming increasingly common in manufacturing of advanced-node semiconductors, where data ...
Proteins need to fold into specific shapes to perform their functions in cells, but they occasionally misfold, which can ...
The engagement establishes a multi-phase framework to support AI enabled capital efficient development of Teverelix, a next generation GnRH antagonist, as a first in class market product for acute ...
Jessica Lin and Zhenqi (Pete) Shi from Genentech describe a novel machine learning approach to predicting retention times for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback